Concepedia

Shuya Wang

SW

16

Publications

663

Citations

14

H-Index

1998

Active since

Affiliations

Novartis (United States)(Current)

Jinan Central Hospital

Shandong University

Shandong First Medical University

Novartis (Switzerland)

Shuya Wang is an author at Novartis (United States) specializing in medicine, physiology, and pharmacology.

ORCID

Top concepts

Publications per year

1998–2023

16

Publications

16

Pancreatic beta-cell K(ATP) channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinide.

S. L. Hu, Shuya Wang, Brian Fanelli et al. · PubMed · 2000 · 127 citations

, , +22

microRNA-21 regulates astrocytic reaction post-acute phase of spinal cord injury through modulating TGF-β signaling

Ronghan Liu, Wenzhao Wang, Shuya Wang et al. · Aging · 2018 · 74 citations · Full text

Pancreatic β-Cell KATP Channel Activity and Membrane-Binding Studies with Nateglinide: A Comparison with Sulfonylureas and Repaglinide

Shiling Hu, Shuya Wang, Barbara Fanelli et al. · Journal of Pharmacology and Experimental Therapeutics · 2000 · 69 citations

Tissue selectivity of antidiabetic agent nateglinide: study on cardiovascular and beta-cell K(ATP) channels.

S. L. Hu, Shuya Wang, Beth E. Dunning · PubMed · 1999 · 63 citations

, , +18

Fexofenadine inhibits TNF signaling through targeting to cytosolic phospholipase A2 and is therapeutic against inflammatory arthritis

Ronghan Liu, Yuehong Chen, Wenyu Fu et al. · Annals of the Rheumatic Diseases · 2019 · 54 citations · Full text

Rows per page

1–5 of 16